Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

Inclusion criteria: * Participant has a diagnosis of chronic kidney disease, with Kidney Disease Outcomes Quality Initiative (KDOQI) Stage 3, 4 or 5, not receiving dialysis; with an Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73 m\^2 estimated using the abbreviated 4-variable Modification of Diet in Renal Disease (MDRD) equation. * The mean of the Participant's three most recent Hb values during the Screening period, obtained at least 4 days apart, must be less than or equal to 10.0 g/dL, with a difference of less than or equal to 1.0 g/dL between the highest and the lowest values. The last Hb value must be within 10 days prior to randomization. * Participant has a ferritin level greater than or equal to 30 ng/mL (greater than or equal to 67.4 pmol/L) at screening. * Participant has a transferrin saturation (TSAT) level greater than or equal to 5% at screening. * Participant has a serum folate level greater than or equal to lower limit of normal at screening. * Participant has a serum vitamin B12 level greater than or equal to lower limit of normal at screening. * Participant's alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels are less than or equal to 3 x upper limit of normal (ULN), and total bilirubin (TBL) is less than or equal to 1.5 x ULN. * Participant's body weight is 45.0 kg up to a maximum of 160.0 kg. Exclusion criteria: * Participant has received any ESA treatment within 12 weeks prior to randomization. * Participant has had …